



Actinogen Medical

ASX ANNOUNCEMENT

Changes to the Actinogen Medical Board

Sydney, 5 October 2016: Actinogen Medical Limited (ASX: ACW) Chairman, Martin Rogers, today announced that he will retire from the Board with effect from the Actinogen Medical Limited Annual General Meeting in November 2016.

Mr Rogers has been Chairman of Actinogen Medical since the acquisition of the Alzheimer's dementia asset in late 2014.

The resignation of Mr Rogers is effective from and conditional on shareholders approving certain amendments to the terms of Mr Rogers' participation in the Actinogen Medical employee share plan.

Dr Ketelbey thanked Mr Rogers for his valuable contribution to the Board and outstanding service to Actinogen Medical.

"We wish Martin all the best for the future with his venture investments and will miss his counsel and judgement."

A search will commence immediately for a replacement Chairman for Actinogen Medical. If the process has not concluded by the AGM, Dr Jason Loveridge will be appointed interim Chairman until an appropriate replacement is identified.

ENDS

Actinogen Medical

Dr Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.